CASI Pharmaceuticals, Inc. (CASI) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

CASI Pharmaceuticals, Inc. (CASI) Healthcare & Pipeline Overview

CASI Pharmaceuticals, Inc. develops and commercializes pharmaceutical products, focusing on hematological cancers. With a pipeline including EVOMELA and CNCT19, CASI targets markets in China, the United States, and internationally, navigating the competitive biotechnology landscape with licensing and distribution agreements.

What Is the Investment Thesis for CASI?

CASI Pharmaceuticals presents a focused investment opportunity within the biopharmaceutical sector, primarily targeting the Chinese and U.S. markets. A key value driver is the advancement of its pipeline, particularly CNCT19, a CAR-T therapy, and BI-1206, an anti-FcγRIIB antibody, both in clinical trials. Successful clinical trial outcomes and subsequent regulatory approvals could significantly increase shareholder value. The company's existing commercial product, EVOMELA, provides a revenue stream, although its profitability is constrained by a negative profit margin of -183.9%. Growth catalysts include potential partnerships and licensing agreements, as well as expansion into new therapeutic areas. Potential risks include clinical trial failures, regulatory hurdles, and competition from established players in the oncology market. The company's beta of 0.89 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

CASI Key Highlights

• Market capitalization of $2.33M indicates a small-cap company with potential for growth but also higher risk.
• Gross margin of 35.8% reflects the company's ability to generate revenue from its product sales, although this needs to translate into overall profitability.
• Profit margin of -183.9% highlights significant challenges in achieving profitability, requiring close monitoring of operating expenses and revenue growth.
• The company has 233 employees, indicating a relatively lean operation for a biopharmaceutical company with both development and commercialization activities.
• CASI has multiple licensing and distribution agreements, suggesting a strategic approach to expanding its market reach and product portfolio.

Who Are CASI's Competitors?

CASI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CASI's Key Strengths?

• Diverse product pipeline targeting hematological cancers.
• Strategic partnerships and licensing agreements.
• Focus on the Chinese market.
• Commercialized product (EVOMELA) generating revenue.

What Are CASI's Weaknesses?

• Negative profit margin.
• Reliance on clinical trial success.
• Limited financial resources compared to larger competitors.
• Dependence on regulatory approvals.

What Could Drive CASI Stock Higher?

• Clinical trial results for CNCT19 in B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL).
• Data readouts from Phase I/II trials of BI-1206 in combination with anti-PD1 therapy Keytruda for solid tumors.
• Regulatory submissions for key pipeline products in China and the United States.
• Expansion of strategic partnerships and licensing agreements to enhance the product portfolio.
• Commercialization efforts for EVOMELA in existing and new markets.

What Are the Key Risks for CASI?

• Financial-distress signal — its Altman Z-Score of -47.99 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for key pipeline products, leading to delays or discontinuation of development.
• Regulatory hurdles and delays in obtaining approvals for new therapies.
• Competition from established pharmaceutical companies with greater resources and market share.
• Dependence on strategic partnerships and licensing agreements, which could be terminated or altered.
• Economic and political instability in China, impacting market access and commercial operations.

What Are the Growth Opportunities for CASI?

• Expansion of CNCT19 CAR-T Therapy: CASI's CNCT19, an autologous CD19 CAR-T investigative product, represents a significant growth opportunity in treating B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). The CAR-T therapy market is projected to grow substantially, driven by the increasing prevalence of hematological malignancies and the high efficacy of CAR-T therapies. Successful clinical trials and regulatory approval in China and the United States could lead to substantial revenue growth for CASI. Timeline: Ongoing clinical trials with potential for regulatory submissions within the next 2-3 years.
• Development of BI-1206 in Combination Therapies: BI-1206, currently in Phase I/II trials in combination with anti-PD1 therapy Keytruda for solid tumors and with MabThera (rituximab) for relapsed/refractory NHL, offers a promising growth avenue. The combination therapy approach aims to enhance the efficacy of existing treatments and address unmet needs in cancer therapy. Positive clinical data and subsequent regulatory approvals could position BI-1206 as a valuable asset in CASI's portfolio. Timeline: Ongoing clinical trials with potential for Phase III trials in the next 2-4 years.
• Commercialization of CID-103 for Multiple Myeloma: CID-103, a product in CASI's pipeline for the treatment of patients with multiple myeloma, presents a growth opportunity in the expanding market for myeloma therapies. The increasing incidence of multiple myeloma and the demand for novel treatment options drive market growth. Successful development and commercialization of CID-103 could contribute significantly to CASI's revenue stream. Timeline: Ongoing development with potential for clinical trials in the next 1-2 years.
• Strategic Partnerships and Licensing Agreements: CASI's strategy of forming partnerships and licensing agreements with companies like Juventas Cell Therapy Ltd and BioInvent International AB provides access to innovative technologies and expands its product portfolio. These collaborations can accelerate the development and commercialization of new therapies, reducing risk and leveraging external expertise. Expanding these partnerships could drive future growth for CASI. Timeline: Ongoing, with potential for new agreements in the next 1-2 years.
• Expansion in the Chinese Market: CASI's focus on the Chinese market, through distribution agreements with companies like China Resources Pharmaceutical Commercial Group International Trading Co., Ltd, offers significant growth potential. The Chinese pharmaceutical market is one of the largest and fastest-growing in the world, driven by increasing healthcare spending and a large patient population. Successfully navigating the regulatory landscape and expanding its commercial presence in China could drive substantial revenue growth for CASI. Timeline: Ongoing, with continuous efforts to expand market access and sales in China.

What Opportunities Does CASI Have?

• Expansion of CAR-T therapy (CNCT19).
• Development of BI-1206 in combination therapies.
• Growth in the Chinese pharmaceutical market.
• Acquisition or licensing of new products.

What Threats Does CASI Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from established pharmaceutical companies.
• Patent expirations.

What Are CASI's Competitive Advantages?

• Proprietary drug formulations and intellectual property.
• Strategic partnerships and licensing agreements.
• Focus on the Chinese pharmaceutical market.
• Expertise in developing and commercializing oncology therapies.

What Does CASI Do?

CASI Pharmaceuticals, Inc., established in 1991 and rebranded from EntreMed, Inc. in 2014, is a biopharmaceutical company dedicated to the development and commercialization of innovative therapeutics. Headquartered in Rockville, Maryland, CASI focuses on addressing unmet medical needs, particularly in hematological cancers. The company's marketed product, EVOMELA, an intravenous formulation of melphalan, is used as a conditioning treatment before stem cell transplantation and as a palliative treatment for multiple myeloma patients. CASI's pipeline includes CNCT19, an autologous CD19 CAR-T investigative product targeting B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). Additionally, BI-1206 is in Phase I/II trials for solid tumors and relapsed/refractory NHL, while CB-5339 is in Phase I for acute myeloid leukemia and myelodysplastic syndrome. Other pipeline products include CID-103 for multiple myeloma, Thiotepa for haemopoietic stem cell transplants, and Octreotide for acromegaly and neuroendocrine tumors. CASI strategically partners through licensing agreements with companies like Juventas Cell Therapy Ltd and BioInvent International AB, and distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd, expanding its reach and capabilities. CASI operates in China, the United States, and internationally.

What Products and Services Does CASI Offer?

• Develops and commercializes therapeutics and pharmaceutical products.
• Focuses on treatments for hematological cancers and other unmet medical needs.
• Offers EVOMELA for conditioning treatment prior to stem cell transplantation and palliative treatment for multiple myeloma.
• Develops CNCT19, a CAR-T therapy for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.
• Conducts clinical trials for BI-1206 in combination with other therapies for solid tumors and NHL.
• Advances CB-5339 in clinical trials for acute myeloid leukemia and myelodysplastic syndrome.
• Seeks regulatory approvals for its pipeline products in China, the United States, and internationally.

How Does CASI Make Money?

• Develops pharmaceutical products internally and through licensing agreements.
• Commercializes products through its own sales force and distribution agreements.
• Generates revenue from product sales, primarily EVOMELA.
• Invests in research and development to expand its product pipeline.

What Industry Does CASI Operate In?

CASI Pharmaceuticals operates within the competitive biotechnology industry, characterized by high R&D spending, lengthy regulatory approval processes, and intense competition. The global biotechnology market is projected to reach significant growth in the coming years, driven by advancements in genomics, personalized medicine, and novel drug delivery systems. CASI's focus on hematological cancers positions it within a growing segment, but it faces competition from larger pharmaceutical companies and specialized biotech firms. The company's strategic partnerships and focus on the Chinese market provide a potential edge in navigating the complex regulatory landscape and accessing a large patient population.

Who Are CASI's Key Customers?

• Hospitals and medical centers.
• Oncologists and hematologists.
• Patients with hematological cancers, such as multiple myeloma, leukemia, and lymphoma.
• Stem cell transplant centers.

How CASI Pharmaceuticals, Inc. Is Valued

CASI Pharmaceuticals, Inc. carries a market capitalization of $2.33M, placing it in the micro-cap category. Relative to its peer group, CASI's quantitative score of 47/100 is below the peer average of 84/100.

ROE 204%Key Financial Metrics

Return on equity for CASI Pharmaceuticals, Inc. stands at 203.9%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.27 means current liabilities exceed short-term assets, a liquidity point worth watching.

F-Score 3/9Financial Health

CASI Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -47.99 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project CASI Pharmaceuticals, Inc. revenue of about $70.4M for fiscal 2026, with EPS near $-1.41.

CASI Financials

CASI Latest News

CASI Analyst Consensus

CASI MoonshotScore

Latest CASI Pharmaceuticals, Inc. Analysis

Common Questions About CASI (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources